RecruitingPhase 2NCT05619913
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Studying Carcinosarcoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Australia New Zealand Gynaecological Oncology Group
- Principal Investigator
- Clare Scott, AM MB BS PhD, MD, PhDPeter MacCallum Cancer Centre, Australia
- Intervention
- Eribulin Mesylate(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (6)
- Prince of Wales Hospital, Randwick, New South Wales, Australia
- Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
- Monash Health, Clayton, Victoria, Australia
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
- Princess Margaret Hospital, Toronto, Ontario, Canada
- Imperial College London, London, United Kingdom
Collaborators
Eisai Inc. · Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05619913 on ClinicalTrials.govOther trials for Carcinosarcoma of the corpus uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07029399A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsNiKang Therapeutics, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT05147558A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsImmatics US, Inc.